KG
Therapeutic Areas
Evofem Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Phexxi® | Hormone-free, on-demand prescription contraception | Approved |
| Solosec® (secnidazole) | Treatment of bacterial vaginosis (BV) and trichomoniasis | Approved |
| EVO200 | Prevention of recurrent Bacterial Vaginosis (BV) | Phase 1 |
Leadership Team at Evofem Biosciences
SP
Saundra Pelletier
Chief Executive Officer, President, and Interim Chair of the Board
IZ
Ivy Zhang
Chief Financial Officer and Secretary
AR
Amy Raskopf
Chief Business Development Officer
ET
Ellen Thomas
Chief of Staff
KK
Kim Kamdar, Ph.D.
Board Member
TO
Tony O'Brien
Board Member